Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuron (IMRN) Cash from Operations (2016 - 2024)

Immuron's quarterly Cash from Operations came in at 2611499.82 in Q4 2024, down 100.19% year-on-year from 1339354581.49 in Q1 2024, and down 100.19% quarter-over-quarter from 1304478.16 in Q4 2023.

Immuron has reported Cash from Operations for 8 years, with the latest figure at 2611499.82 in Q4 2024.

  • For the quarter ending Q4 2024, Cash from Operations fell 100.19% year-over-year to 2611499.82; the trailing twelve-month figure through Dec 2024 stood at 7617399.98 (down 15.94% YoY), and the FY2025 full-year result was 6136949.0, down 4.37% from the prior year.
  • Cash from Operations for Q4 2024 stood at 2611499.82, down from 1304478.16 in the prior quarter.
  • The five-year high for Cash from Operations was 992017.0 in Q4 2022, with the low at 2709405.0 in Q4 2020.
  • Average Cash from Operations over 4 years is 1904349.99, with a median of 1957988.99 recorded in 2023.
  • Year-over-year, Cash from Operations slumped 31.5% in 2023 and tumbled 100.19% in 2024.
  • Tracing IMRN's Cash from Operations over 4 years: stood at 2709405.0 in 2020, then jumped by 63.39% to 992017.0 in 2022, then tumbled by 31.5% to 1304478.16 in 2023, then plunged by 100.19% to 2611499.82 in 2024.
  • The last three Cash from Operations figures came in at 2611499.82 (Q4 2024), 1304478.16 (Q4 2023), and 992017.0 (Q4 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -1.67 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -12.20 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -2.49 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.43 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.08 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 70.50 Mn
10 Immuron 1.27 Bn 1.27 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 -2.61 Mn
Dec 31, 2024 -2.61 Mn
Dec 31, 2023 -1.30 Mn
Dec 31, 2023 -1.30 Mn
Dec 31, 2022 -992,017.00
Dec 31, 2022 -992,017.00
Dec 31, 2020 -2.71 Mn
Dec 31, 2020 -2.71 Mn
Dec 31, 2019 -1.56 Mn
Dec 31, 2019 -1.56 Mn
Dec 31, 2018 -424,940.00
Dec 31, 2018 -424,940.00
Dec 31, 2017 -2.48 Mn
Dec 31, 2017 -2.48 Mn
Dec 31, 2016 1.67 Mn
Dec 31, 2016 1.67 Mn